Key result
Ultrasound-guided subacromial plus acromioclavicular joint injection and suprascapular nerve block maintained significant pain reduction at 24 weeks compared to subacromial injection alone (p<0.001).
Why the study?
Acromioclavicular joint pathologies may be a common etiological factor with subacromial impingement syndrome and should be considered in treatment alongside standard subacromial injection or suprascapular nerve block.
Does combined subacromial and acromioclavicular joint injection or suprascapular nerve block improve pain and function compared to subacromial injection alone in patients with shoulder subacromial impingement syndrome?
Population
90 patients with chronic shoulder pain associated with SIS
Comparison
US-guided SA injection vs US-guided SA+ACJ injection vs US-guided SSNB
Design
Prospective, randomized, single-blind controlled trial
Follow-up
24th week
Authors
Loading...
May support combined injections for sustained shoulder pain relief; hypothesis-generating pending randomized confirmation.
RCT (n=90)
Single-blind
Random number table
No
Does combined subacromial and acromioclavicular joint injection or suprascapular nerve block improve pain and function compared to subacromial injection alone in patients with shoulder subacromial impingement syndrome?
Absolute Event Rate: 22% vs 30%
p-value: p=<0.001
In patients with subacromial impingement syndrome, suprascapular nerve block and combined subacromial/acromioclavicular joint injections provide better long-term pain and functional improvement at 24 weeks compared to subacromial injection alone.
Ökmen et al. (2024) conducted an RCT in Shoulder subacromial impingement syndrome (SIS) (n=90). Ultrasound-guided subacromial plus acromioclavicular joint injection or suprascapular nerve block vs. Ultrasound-guided subacromial injection alone was evaluated on Visual analogue scale (VAS) score at 24 weeks (p=<0.001). Ultrasound-guided subacromial plus acromioclavicular joint injection and suprascapular nerve block maintained significant pain reduction at 24 weeks compared to subacromial injection alone (p<0.001).
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: